CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Barcelona, Spain and 125 other locations
mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...
Phase 1
Barcelona, Catalunya, Spain and 23 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Barcelona, Spain and 46 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Barcelona, Catalunya, Spain and 93 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Barcelona, Spain and 176 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
Barcelona, Spain and 70 other locations
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Phase 1
Barcelona, Spain and 26 other locations
chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...
Phase 3
Barcelona, Spain and 74 other locations
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...
Phase 2
Barcelona, Spain and 20 other locations
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...
Phase 3
Barcelona, Cataluña, Spain and 119 other locations
Clinical trials
Research sites
Resources
Legal